Tango Therapeutics (TNGX) Equity Average: 2020-2025
Historic Equity Average for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to $147.5 million.
- Tango Therapeutics' Equity Average fell 38.14% to $147.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.5 million, marking a year-over-year decrease of 38.14%. This contributed to the annual value of $226.3 million for FY2024, which is 9.94% down from last year.
- Latest data reveals that Tango Therapeutics reported Equity Average of $147.5 million as of Q3 2025, which was down 2.23% from $150.9 million recorded in Q2 2025.
- In the past 5 years, Tango Therapeutics' Equity Average registered a high of $355.1 million during Q4 2021, and its lowest value of $5.0 million during Q2 2021.
- In the last 3 years, Tango Therapeutics' Equity Average had a median value of $238.4 million in 2023 and averaged $219.7 million.
- As far as peak fluctuations go, Tango Therapeutics' Equity Average soared by 7,272.09% in 2021, and later slumped by 41.09% in 2025.
- Quarterly analysis of 5 years shows Tango Therapeutics' Equity Average stood at $355.1 million in 2021, then dropped by 26.42% to $261.3 million in 2022, then grew by 1.37% to $264.9 million in 2023, then fell by 19.07% to $214.3 million in 2024, then slumped by 38.14% to $147.5 million in 2025.
- Its Equity Average stands at $147.5 million for Q3 2025, versus $150.9 million for Q2 2025 and $183.1 million for Q1 2025.